[Bioregulating therapy and life quality in aged patients with hypertonic angioretinopathy].
The researches data of influence of vascular impair of a retina in aged patients with arterial hypertension (AH) on their life quality (LQ) are given in the article. The questionnaires "The Scale of an estimation of life quality", SF-36 and VF-16 in authors updating were used. Ultrasonic dopplerography of retina vessels in patients with hypertonic angioretinopathy showed the authentic decrease of maximal systolic speeds of a blood-groove of an orbital artery, increase in its index of resistance and decrease of ophthalmic-retinal factor in comparison with normal parameters in the given age group. The studying of the comparative analysis of change of LQ and visual functions of aged patients with hypertonic angioretinopathy under adding to complex hypotensive therapies the Cortexin (the basic group, 28 people) and Actovegin (control group, 30 people) was held. As a result of treatment disappearance or reduction of visual discomfort and improvement of the emotional condition of 61% of patients of the basic group and 36% of patients of control group were marked. Improvement of LQ and subjective quality of eyesight correlated with improvement of visual functions. Thus, the researches enable to include people of elderly and senile age with AH into group of risk with probable decrease in visual functions; inclusion the neuro-protector cortexin in complex treatment of elderly and senile patients with AH and changes in eye-bottom considerably raises and stabilizes LQ and quality of eyesight of these patients.
Trofimova
S V
SV
Atakhanova
L E
LE
Akhmedova
E P
EP
D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use; D005260:Female; D006418:Heme / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011788:Quality of Life; D012039:Regional Blood Flow; D012164:Retinal Diseases / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D012171:Retinal Vessels / Q000503:physiopathology; D011795:Surveys and Questionnaires
D000975:Antioxidants; D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; D006418:Heme; C015646:Actovegin; C056590:cortexin